Bone turnover markers in patients with type 1 Gaucher disease
نویسندگان
چکیده
Bone complications occur frequently in Gaucher disease (GD) and reduce the quality of life of these patients. Skeletal involvement is an important indication for treatment to ameliorate symptoms and reduce the risk of irreversible and debilitating disease. Bone biomarkers have been used to assess disease status and the response to therapy in a number of bone disorders. Here, we examine the literature for evidence of abnormalities in bone turnover markers in patients with type 1 GD to assess whether they might be useful for the assessment of bone involvement in GD. We have found that bone biomarkers in GD show highly variable results which do not currently support their routine use for clinical assessment of bone status, as an indication for therapy initiation, or for monitoring the response to therapy. A greater understanding of bone markers and their relation to the bone manifestations of GD is required.
منابع مشابه
بررسی ارتباط سطح سرمی مارکرهای ساخت و تخریب استخوانی با فعالیت التهابی بیماری در بیماران مبتلا به آرتریت روماتوئید مراجعه کننده به بیمارستان لقمان حکیم طی سال 88 – 1387
Background: Rheumatoid arthritis (RA) is the most common inflammatory arthritis affecting 0.5 to 1% of the general population worldwide. The cause of RA remains unknown. In active RA, bone turnover markers change in serum and urine before the appearance of erosions in radiography. In this study, we compared RA activity index with bone turnover marker levels in serum of RA patients. Methods:...
متن کاملReal-world clinical experience with long-term miglustat maintenance therapy in type 1 Gaucher disease: the ZAGAL project.
There are few published data from real-world clinical experience with miglustat (Zavesca), an oral inhibitor of glucosylceramide synthase, in type 1 Gaucher disease. We report data from a prospective, open-label investigational study that evaluated substrate reduction therapy with miglustat 100 mg t.i.d. as a maintenance therapy in patients with Type 1 Gaucher disease who had been switched from...
متن کاملEffects of Oral Isotretinoin on Serum Vitamin D Metabolites and Other Biochemical Markers of Bone Turnover and Calcium Homeostasis in Severe Acne
Background: Few studies have investigated on vitamin D metabolites Serum levels, and calcium homeostasis in humans receiving retinoids, despite a substantial amount of literature concerning retinoid-induced osteoporosis in animals. We prospectively measured vitamin D metabolites serum levels and calcium homeostasis and radiographic bone changes in short course treatment with oral isotreti...
متن کاملOutcomes after 18 months of eliglustat therapy in treatment‐naïve adults with Gaucher disease type 1: The phase 3 ENGAGE trial
Eliglustat, an oral substrate reduction therapy, is a first-line treatment for adults with Gaucher disease type 1 (GD1) who are poor, intermediate, or extensive CYP2D6 metabolizers (>90% of patients). In the primary analysis of the Phase 3 ENGAGE trial (NCT00891202), eliglustat treatment for 9 months resulted in significant reductions in spleen and liver volumes and increases in hemoglobin conc...
متن کاملA Phase 2 Multi-center, Open-label, Switch-over Trial to Evaluate the Safety and Efficacy of Abcertin® in Patients with Type 1 Gaucher Disease
Gaucher disease is a lysosomal storage disease for which enzyme replacement therapy has proven to be effective. A switch-over clinical trial was performed to evaluate the efficacy and safety of Abcertin® (ISU Abxis, Seoul, Korea) in subjects with type 1 Gaucher disease who were previously treated with imiglucerase. Five Korean patients with type 1 Gaucher disease were enrolled. Previous doses o...
متن کامل